ArticleInternational journal of molecular sciences2022
Anti-Inflammatory Action of Dexmedetomidine on Human Microglial Cells.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 18 citations in OpenAlex.
- Different Sedation Strategies in Older Patients Receiving Spinal Anesthesia for Hip Surgery on Postoperative Delirium: A Randomized Clinical Trial.Drug design, development and therapy · 2023Trial
- Effect of Intraoperative Dexmedetomidine Use on Postoperative Liver Function and Graft Outcomes in Laparoscopic Living Donor Hepatectomy: A Propensity Score-Matched Study.Journal of clinical medicine · 2026Article
- Real-World Evidence for Combination Sedation: Propofol Plus Dexmedetomidine and Clinical Outcomes in Mechanically Ventilated ICU Patients.Therapeutics and clinical risk management · 2026Article
- HMC3 revealed: how much do these "Microglia" really tell us?Frontiers in immunology · 2026Review
- Effects of intravenous dexmedetomidine on hemodynamic stability, inflammatory factors, and brain injury biomarkers in patients with Moyamoya disease undergoing revascularization surgery.American journal of translational research · 2026Article
- Delirium Management in Critical Care: Are We Moving Forward or Still Treading Water?Medical sciences (Basel, Switzerland) · 2025Review
- Sex- and cell type-specific effects of dexmedetomidine on ferroptosis in neurons and microglia following traumatic brain injury in juvenile mice.Molecular neurobiology · 2025Article
- Article
- Network pharmacology and experimental validation reveal dexmedetomidine's protective mechanisms against acute liver injury in mice.Scientific reports · 2025Article
- Novel applications of sleep pharmacology as delirium therapeutics.Sleep medicine reviews · 2025Review
- Perioperative dexmedetomidine effects on delirium in elderly patients after noncardiac surgery: A retrospective propensity score analysis.Frontiers in pharmacology · 2025Article
- Inhibiting the Cholesterol Storage Enzyme ACAT1/SOAT1 in Myelin Debris-Treated Microglial Cell Lines Activates the Gene Expression of Cholesterol Efflux Transporter ABCA1.Biomolecules · 2024Article
- Impact of dexmedetomidine-assisted anesthesia in elderly patients undergoing radical resection of colon cancer.World journal of gastrointestinal surgery · 2024Article
- Effect of General Anesthetic Agents on Microglia.Aging and disease · 2024Review
- Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database.Frontiers in pharmacology · 2024Article
- Taming Postoperative Delirium with Dexmedetomidine: A Review of the Therapeutic Agent's Neuroprotective Effects following Surgery.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Antioxidant Cascade Nanoenzyme Antagonize Inflammatory Pain by Modulating MAPK/p-65 Signaling Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Neuroinflammation, where inflammatory cytokines are produced in excess, contributes to the pathogenesis of delirium. Microglial cells play a central role in neuroinflammation by producing and releasing inflammatory cytokines in response to infection, tissue damage and neurodegeneration. Dexmedetomidine (DEX) is a sedative, which reduces the incidence of delirium. Thus, we hypothesized that DEX may alleviate delirium by exhibiting anti-inflammatory action on microglia. In the present study, we investigated the anti-inflammatory action of DEX on human microglial HMC3 cells. The results indicated that DEX partially suppressed the IL-6 and IL-8 production by lipopolysaccharide (LPS)-stimulated HMC3 cells as well as the phosphorylation of p38 MAPK and IκB and the translocation of NF-κB. Furthermore, DEX substantially suppressed IL-6 and IL-8 production by unstimulated HMC3 cells as wells as the phosphorylation of p38 MAPK and IκB and the translocation of NF-κB. These observations suggest that DEX exhibits anti-inflammatory action on not only LPS-stimulated but also unstimulated microglial cells via the suppression of inflammatory signaling and cytokine production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.